Evidence map›Paper›PMID 40450458›Full record

ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2025

Neuroprotective effects of G9a inhibition and cannabinoid receptor activation in Alzheimer's disease through a pharmacological approach.

Aina Bellver-Sanchis, Marta Ribalta-Vilella, Jaume Lillo, Daniel Ortuño-Sahagún, Rafael Franco, Mercè Pallàs, Gemma Navarro, Christian Griñán-Ferré

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Aina Bellver-SanchisDepartment of Pharmacology and Therapeutic Chemistry, Institut de Neurociències-Universitat de Barcelona, Avda. Joan XXIII, 27, 08028 Barcelona, Spain.
Marta Ribalta-VilellaFacultat de Farmàcia i Ciències de l'Alimentació or Facultat de Biologia (Depending on the Faculty You Are Registered with), Universitat de Barcelona, Avda. Diagonal 643, 08028 Barcelona, Spain.
Jaume LilloNetwork Center for Biomedical Research in Neurodegenerative Diseases, CiberNed, Spanish National Health Institute Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain; Institut de Neurociències UB, Campus Mundet, Passeig de la Vall d'Hebron 171, 08035 Barcelona, Spain; Molecular Neurobiology Laboratory, Department Biochemistry and Molecular Biomedicine, Facultat de Biologia, Universitat de Barcelona, 08028 Barcelona, Spain.
Daniel Ortuño-SahagúnLaboratorio de Neuroinmunobiología Molecular, Instituto de Investigación en Ciencias Biomédicas, Departamento de Biología Molecular y Genómica. Universidad de Guadalajara, Guadalajara, Mexico.
Rafael FrancoNetwork Center for Biomedical Research in Neurodegenerative Diseases, CiberNed, Spanish National Health Institute Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain; Department of Biochemistry and Physiology, School of Pharmacy and Food Sciences, Universitat de Barcelona, 08028 Barcelona, Spain; School of Chemistry, University of Barcelona, 08028 Barcelona, Spain.
Mercè PallàsDepartment of Pharmacology and Therapeutic Chemistry, Institut de Neurociències-Universitat de Barcelona, Avda. Joan XXIII, 27, 08028 Barcelona, Spain; Spanish Biomedical Research Center in Neurodegenerative Diseases (CIBERNED)-Instituto de Salud Carlos III, Madrid, Spain.
Gemma NavarroNetwork Center for Biomedical Research in Neurodegenerative Diseases, CiberNed, Spanish National Health Institute Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain; Institut de Neurociències UB, Campus Mundet, Passeig de la Vall d'Hebron 171, 08035 Barcelona, Spain; Department of Biochemistry and Physiology, School of Pharmacy and Food Sciences, Universitat de Barcelona, 08028 Barcelona, Spain.
Christian Griñán-FerréDepartment of Pharmacology and Therapeutic Chemistry, Institut de Neurociències-Universitat de Barcelona, Avda. Joan XXIII, 27, 08028 Barcelona, Spain; Spanish Biomedical Research Center in Neurodegenerative Diseases (CIBERNED)-Instituto de Salud Carlos III, Madrid, Spain. Electronic address: Christian.grinan@ub.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epigenetic alterations are key contributors to Alzheimer's disease (AD), driving age-related cognitive decline. This study explores the combined neuroprotective effects of G9a histone methyltransferase inhibition (via UNC0642) and cannabinoid receptor activation (CB1R: ACEA; CB2R: JWH133) in AD models. We used HEK-293T cells and hippocampal neurons to demonstrate that G9a inhibition selectively enhances CB1R-mediated ERK/cAMP signaling. In SAMP8 mice (sporadic AD model), we evaluated the effects of pharmacological inhibition of G9a (UNC0642), combined with CB

Indexed as

Alzheimer DiseaseCannabinoid Receptor AgonistsHistone-Lysine N-MethyltransferaseNeuroprotective AgentsReceptor, Cannabinoid, CB1AnimalsCannabinoidsHEK293 CellsHippocampusHumansIndolesMaleMiceNaphthalenesReceptor, Cannabinoid, CB2Receptors, Cannabinoid1,1-dimethylbutyl-1-deoxy-Delta(9)-THCCannabinoid Receptor AgonistsCannabinoidsG9a protein, mouseHistone-Lysine N-MethyltransferaseIndolesNaphthalenesNeuroprotective AgentsReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2Receptors, CannabinoidBehaviorCannabinoidsHistone methyltransferaseNeurodegenerative diseasesNeuroinflammationSynaptic plasticity

Identifiers

PMID40450458
PMCPMC12491791

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.